Overview

Long-term Use of Takepron Capsules on the Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Low-dose Aspirin

Status:
Completed

Trial end date:
2014-01-01

Target enrollment:
0

Participant gender:
All

Summary

The purpose of this study is to investigate the safety and efficacy of long-term administration of lansoprazole (Takepron) for up to 12 months in the routine clinical setting in patients receiving low-dose aspirin

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Takeda

Treatments:

Aspirin
Dexlansoprazole
Lansoprazole

Criteria

Inclusion Criteria:

- (1) Patients with a history of gastric or duodenal ulcers (2) Patients requiring
long-term use of low-dose aspirin (81-324 mg once daily) as prophylaxis for
thromboembolism (3) Patients taking low-dose oral aspirin (81-324 mg once daily) at
the start of administration of lansoprazole (including patients who start low-dose
aspirin on the same day as the start of administration of lansoprazole)

Exclusion Criteria:

- (1) Patients with gastric or duodenal ulcer (in the active [A1, A2] or healing [H1,
H2] stage if assessed endoscopically) at the start of administration of lansoprazole
(2) Patients with active upper gastrointestinal hemorrhage at the start of
administration of lansoprazole (3) Patients with contraindications for lansoprazole